OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
March 02, 2021
Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.
January 07, 2021
The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.
January 02, 2021
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
October 29, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.
October 16, 2020
The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.
October 02, 2020
Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.
September 14, 2020
The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.
August 13, 2020
The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.
July 02, 2020
Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.